|Day Low/High||35.75 / 36.74|
|52 Wk Low/High||24.21 / 59.25|
Constellation looks to wine, beer, and cannabis to take it higher.
There are several avenues to invest in the potential cannabis boom -- recreational plays; medical plays; and companies that have a lot to gain from the industry but aren't reliant upon it for success.
I have the honor and pleasure of book-ending your week away from Doug. On Friday, we'll get non-farm payroll and the unemployment, so I don't put much stock in the data coming this Thursday morning. Instead, I want to start off the day talking abou...
Constellation looks like a star today after beating expectations.
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.
Expert says weed-related products for pets could become a $55 billion-a-year business.
The only other option is 'to fearfully wait' for the legal-weed industry to expand.
It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.
A look at CGC's charts and our latest strategy.
'There's too much hype too soon,' Canopy Growth chief Bruce Linton says.
Covered calls may be the best bet -- or wait for a dip.
Canadian marijuana legalization and U.S. approval of industrial hemp are coming.
Cannabis companies should be taking advantage of the mania to raise money.
Don't try to explain the stock's meteoric rise on a fundamental or technical basis, because it defies both.
This options trade combines some upside with a chance to buy TLRY at a decent price.
The cannabis company has gained DEA approval to import a cannabinoid drug into the U.S.
Expect more companies to join Coca-Cola, Molson Coors and Constellation Brands in checking out the market.
A tie-up between the two could mark the first major U.S. firm to establish a line of CBD drinks.
The latest reports about Coke looking into cannabis confirms a broader industry trend.
You don't want your money to go up in smoke.
Not every cannabis stock was strong on Wednesday. One significant Canadian name sure was though.
Moody's and Zacks aren't seeing the potential for CBD drinks or even THC drinks.
Hexo is pursuing joint ventures in cosmetics, health care, candy, edibles, and vape companies.
The underlying action, particularly the weakness in the technology sector, is reason for concern.